Analytical Data
-
Gene name
RAMP1
- Application
-
Alternative Names
RAMP1;Receptor activity-modifying Protein 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60894
-
Expression Region
27-117aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSCQEANYG ALLRELCLTQ FQVDMEAVGE TLWCDWGRTI RSYRELADCT WHMAEKLGCF WPNAEVDRFF LAVHGRYFRS CPISGRAVRD PPGS
-
Molecular Weight
13 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RAMP1 (Receptor Activity-Modifying Protein 1) is a crucial molecular component that modulates the function of G protein-coupled receptors (GPCRs), particularly the calcitonin gene-related peptide (CGRP) receptor. It plays a significant role in enhancing receptor signaling and specificity, influencing various physiological processes such as vasodilation, pain perception, and neurogenic inflammation. The study of RAMP1 has gained prominence due to its implications in various pathophysiological conditions, including migraine and cardiovascular diseases. Research has demonstrated that RAMP1 can influence the pharmacological properties of CGRP receptors, making it a potential therapeutic target for designing novel drugs to alleviate migraine symptoms and manage cardiovascular health. Additionally, investigations into the structural and functional characteristics of RAMP1 provide insights into GPCR biology and signaling pathways, enhancing our understanding of receptor modulation. Given the increasing recognition of GPCRs in drug discovery, RAMP1 research is essential for elucidating the molecular mechanisms underlying receptor function and developing effective strategies for therapeutic intervention. Thus, RAMP1 serves as a significant focus in both basic and applied biomedical research, with the potential to pave the way for innovative treatments for chronic conditions related to dysregulated receptor activity.
